Parenteral Drugs (India) Ltd.
Snapshot View

3.70 0.00

20 May 2022, 03:31:19 PM
Volume: 0

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.pdindia.com
Market Cap 11.03 Cr.
Enterprise Value(EV) 118.28 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -41.93 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share -286.79 Trailing Twelve Months Ending 2021-12
Price to Book Value -0.01 Calculated using Price: 3.70
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 2.98 Cr. 29,816,300 Shares
FaceValue 10
Company Profile

Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies.

Commencing with production of I.V. fluids in polypropylene bottles for the first time ever, as against glass, PDPL has followed up the success in creating single use disposable eye drop It is now set to bring dialysis within the reach of the common man with its innovatively and indigenously made CAPD kits . The company went for a successful public issue in 1994. Using money merely as means to achieve an end, the company has very judiciously applied it to shape out to a reality from the blue print of the dreams of carefully identified areas of potent niche activities. A cost-effective technology at work is evident in every area of its varied production processes. In fact this is one of the rare companies which showcases the use of most modern state-of-the-art technologies co-existing in harmonious synergy with the labor intensive technologies and retained in larger societal interests.

Parenteral Drugs (India)  believes in appropriate and systematic methods and observes highest standard in  letter and spirit. Parenteral Drugs (India)’s quality standards are  truly  high. The company follows a stringent quality control policy, indeed takes quality control measures at every stage of the manufacturing process. The quality assurance department has a well equipped laboratory with most modern testing instrument. The quality policy has resulted in company being conferred upon the ISO 9001:2000 and WHO GMP certification by international bodies. Not just to the products at PDPL quality is pertinent to to every aspect pre-delivery service, delivery and post delivery service. It is a part of the people's attitude in every step from administration production to distribution.

PDPL is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.

Products manufactured by the company includes:

Solid and liquid orals

  • ANTIBIOTICS AND ANTIBACTERIAL
  • ANTIULCERANT
  • ANALGESICS ANTI-INFLAMMATORY
  • MULTIVITAMINS AND MINERALS
  • ANXIOLYTIC
  • ANTIPROTOZOAL
  • ANTICOLD
  • ANTHELMINTIC
  • ANTI-HISTAMINIC
  • MUSCLE RELAXANT
  • CARDIAC
  • ANTIDIABETIC
  • COUGH SYRUP
  • Appetite Enhancer

Injections

1. IV Fluids

  • Electrolytes
  • Antibacterial
  • Energy replenisher
  • Irrigation solution
  • Osmotic diuretic
  • Dialysis solution

2. Eye/ear drops

  • Cigram Drops
  • Gentate Drops
  • Gentate - B Drops
  • Ocuroid Drops
  • Flufen Eye Drops
  • Ikleen Eye Drops

Achievements/ recognition

  • The International Gold Awards.
  • The Udyog Ratna.
  • The company has recently achieved a major break-through in designing CAPD kits for patients with terminal renal failure.
  • Introduction of Ciprofloxacin 400 mg infusion in 200 ml with 5% Dextrose for the first time in our country.

Milestones

  • 1975- Founds Prem Pharmaceuticals (Leader in glass-filled I.V. fluids)
  • 1983- Establishes PDPL (Pioneering Leader in Polypropylene-filled I.V.fluids).
  • 1994- Successful public issue.
  • 1996-Launched First single Use Eye/Ear drop Dispensers using  FFS  technology
  • 1997- Establishes Royal Crystal Pvt. Ltd. [now Diamond Crystal-The only one to  make full lead Crystal Glassware in India]
  • 1998- Launched branded products in Tablets/Capsules/Liquids Orals/I.V.
  • 1998-Establishes Punjab Formulations.
  • 2001-Launched CAPD-the dialysis kit that's affordable by common man and is  superior to the import one.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
-3.90%
3 Month
-6.33%
6 Month
-13.95%
1 Year
-12.94%
2 Year
+42.31%
5 Year
-85.35%
10 Year
-95.00%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -44.85 -23.61 -46.67 -152.43
Return on Capital Employed (%) -5.15 1.90 -2.29 -8.13 -6.91 -5.55 -35.07 -52.31
Return on Assets (%) -12.80 -5.44 -8.41 -12.60 -12.16 -13.17 -23.45 -26.72 -29.65

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 246 202 127 325 -17 -136 -447 -561 -683 -749
Non Curr. Liab. 427 456 427 440 462 370 4 -26 -59 -77
Curr. Liab. 162 166 230 300 428 593 878 1,006 1,144 1,218
Minority Int. 1 1 1 1 0 0 0 0 0 0
Equity & Liab. 835 825 785 1,066 872 827 435 419 402 393
Non Curr. Assets 629 619 549 902 750 727 368 351 334 326
Curr. Assets 192 200 235 163 122 99 67 67 68 67
Misc. Exp. not W/O 14 5 1 1
Total Assets 835 825 785 1,066 872 827 435 419 402 393

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 327 274 263 260 230 224 32 32 12 9
Other Income 0 61 1 2 6 2 1 0 0 0
Total Income 328 334 264 262 236 226 33 32 12 9
Total Expenditure -341 -350 -248 -296 -252 -225 -50 -47 -24 -16
PBIDT -14 -15 15 -34 -17 0 -16 -14 -12 -6
Interest -56 -60 -70 -70 -86 -98 -96 -110 -125 -139
Depreciation -23 -19 -31 -23 -25 -24 -69 -17 -17 -17
Taxation -15 1 19 10 10 10 33 28 33 37
Exceptional Items 47 0 -1 0
PAT -108 -45 -68 -117 -118 -112 -148 -114 -122 -125
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit -108 -45 -68 -117 -118 -112 -148 -114 -122 -125
Adjusted EPS -42 -15 -23 -39 -40 -38 -50 -38 -41 -42

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 20 -168 -60 2 58 134 167 477 112 125
Cash Fr. Inv. -147 -18 33 3 -110 -1 -1 97 0 0
Cash Fr. Finan. 133 182 25 -10 54 -134 -167 -574 -112 -125
Net Change 5 -3 -2 -5 1 0 0 0 0 0
Cash & Cash Eqvt 13 11 8 3 5 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 73.28 73.28 73.28 73.28 73.28 73.28 73.28 73.28 73.29
Public 26.72 26.72 26.72 26.72 26.72 26.72 26.72 26.72 26.71
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 100.00 100.00 100.00 94.51 94.51 94.51 94.51 94.51 94.50

Announcements View Details

Fri, 13 May 2022
General updates
Parenteral Drugs (India) Limited has informed the Exchange about Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participant) Regulation, 2018
Wed, 06 Apr 2022
Disclosure under SEBI Takeover Regulations
Promoter/Promoter Group of Parenteral Drugs (India) Limited has submitted a disclosure under Regulation 31(4) of SEBI Takeover Regulations for the year ended 31-Mar-2022
Tue, 05 Apr 2022
Disclosure under SEBI Takeover Regulations
Promoter/Promoter Group of Parenteral Drugs (India) Limited has submitted a disclosure under Regulation 31(4) of SEBI Takeover Regulations for the year ended 31-Mar-2022

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%